2026 Life Sciences Outlook: Why South Asia's Resilience Could Define the Next Chapter

Executive Summary

The life sciences industry is becoming increasingly borderless, yet sentiment varies sharply across geographies. According to Deloitte's 2026 Life Sciences Outlook Survey, more than 75% of biopharma and medtech executives are confident in their own organizations' financial prospects, but only 41% express optimism about the global economy. This gap underscores the need for companies to balance enterprise-specific momentum with external resilience. For South Asia, a region not directly surveyed but deeply embedded in global life sciences value chains, the findings offer a strategic lens for navigating 2026 and beyond.

Introduction

South Asia's life sciences sector—anchored by India's pharmaceutical production, Bangladesh's generic drug manufacturing, and emerging biotech hubs in Pakistan and Sri Lanka—has become a critical node in global healthcare supply chains. As multinational corporations seek diversified sourcing and regional markets expand, Deloitte's outlook provides a useful benchmark for understanding the forces reshaping the industry. While the survey's Asian sample included only China and Japan, the dynamics it captures—such as AI adoption, regulatory shifts, and market fragmentation—are equally relevant to South Asian stakeholders.

Main Analysis

Global Confidence and Regional Divergence

The survey reveals a striking split: European and Asian biopharma leaders are markedly more optimistic than their US counterparts. Ninety percent of biopharma executives in surveyed European and Asian countries report positive or cautiously positive expectations for 2026, compared to 56% in the United States. Similarly, 83% of the former group predict steady or strong revenue growth, while only 71% of US respondents do. Medtech executives, meanwhile, are broadly more optimistic, with 81% anticipating revenue growth.

For South Asia, these numbers suggest that demand from European and Asian markets may remain robust, even if US headwinds persist. Indian pharmaceutical exports, for instance, rely heavily on both the US and Europe. The divergence implies that South Asian firms with diversified market exposure could be better positioned to weather regional volatility.

AI and Emerging Technologies as Strategic Levers

The report emphasizes that the year ahead will reward organizations that harness artificial intelligence (AI) and emerging technologies while adapting to regulatory and economic change. Life sciences companies globally are investing in AI for drug discovery, clinical trial optimization, manufacturing automation, and supply chain resilience. In South Asia, AI adoption is accelerating in both large pharmaceutical firms and agile startups. India's growing pool of data scientists and software engineers, combined with a robust IT services sector, positions the region as a hub for AI-enabled life sciences innovation.

However, the uptake is uneven. Smaller manufacturers in Bangladesh and Nepal may lack the capital and expertise to integrate advanced analytics. This digital divide could widen competitive gaps within the region unless addressed through policy support and regional cooperation.

Regulatory Dynamics and Market Access

The outlook notes that regulatory and economic change are key challenges. In 2026, companies must navigate evolving frameworks, including the US Food and Drug Administration's enhanced scrutiny of foreign facilities, European Union's pharmaceutical legislation reform, and harmonization efforts in Asia. South Asian regulators are also modernizing: India's Central Drugs Standard Control Organization (CDCSO) has introduced digital submission portals, and Bangladesh is working to align with WHO Good Manufacturing Practices.

For South Asian firms, compliance with global standards remains a perennial challenge. But it also presents an opportunity: those that invest in quality infrastructure and transparent regulatory engagement can gain a competitive edge in export markets.

Regional Impact

The findings carry several implications for South Asia's economic trajectory:

• Economic Growth: A resilient life sciences sector can support GDP expansion through exports, job creation, and innovation spillovers. India's pharmaceutical industry, valued at over $50 billion, contributes significantly to national revenue.
• Regional Competitiveness: Enhanced manufacturing capabilities and digital adoption can help South Asia capture a larger share of global pharmaceutical outsourcing, currently dominated by China and Southeast Asia.
• Trade Integration: As global supply chains diversify, South Asia can emerge as a reliable alternative, particularly in active pharmaceutical ingredients (APIs) and generics.
• Foreign Direct Investment: Multinational companies may increase investment in South Asian production and R&D centers to hedge against geopolitical risks. The survey's emphasis on financial confidence suggests that capital flows could accelerate.
• Technology Adoption: Investment in AI and automation could transform manufacturing efficiency, reducing costs and improving quality, making South Asian products more competitive internationally.
• Employment: The expansion of life sciences manufacturing and digital health services is labor-intensive, offering high-skilled employment opportunities for the region's young workforce.
• Regional Cooperation: Closer collaboration among South Asian countries on regulatory harmonization and cross-border logistics could amplify the region's collective bargaining power.

Strategic Insights

Business Opportunities

South Asian companies should consider leveraging the optimism in European and Asian markets by expanding exports to these regions. The report's finding that 83% of those executives expect revenue growth indicates a favorable demand environment. Additionally, the medtech segment's higher optimism suggests opportunities in medical devices and diagnostics.

Investment Implications

Investors should look at life sciences as a strategic sector within South Asia, particularly firms involved in AI-driven drug discovery, biosimilars, and contract manufacturing. The confidence gap between corporate and global outlooks implies that company-specific fundamentals matter more than macro trends, rewarding thorough due diligence.

Policy Priorities

Governments in South Asia should prioritize infrastructure—both physical and digital—to support the industry. Investments in cold chain logistics, reliable energy, and high-speed internet are essential. Policies that encourage R&D tax incentives, streamlined regulatory approvals, and intellectual property protection will attract foreign direct investment.

Technology as Equalizer

AI and digital tools can help smaller firms leapfrog traditional barriers. Cloud-based quality management systems, blockchain for supply chain traceability, and machine learning for pharmacovigilance are within reach for mid-sized companies if enabling ecosystems are developed. Public-private partnerships can facilitate technology transfer and skills development.

Competitive Risks

The report warns of potential decline: 18% of US biopharma respondents expect revenue declines. If the US market contracts, South Asian exporters reliant on US sales may face headwinds. Diversification into emerging markets and non-pharma life sciences segments can mitigate this risk.

Future Outlook (2026–2030)

Looking ahead, South Asia's life sciences sector is poised for transformative growth, but success hinges on strategic choices.

• Artificial Intelligence: By 2030, AI could become integral to drug discovery and clinical trials across the region. India's bioinformatics talent pool may position the country as a global AI-biotech hub.
• Digital Economy: The proliferation of telemedicine and digital health platforms in South Asia will create massive datasets, enabling personalized medicine. Regulators will need to adapt quickly to protect patient privacy while encouraging innovation.
• Infrastructure: Investments in dedicated pharma parks, port connectivity, and renewable energy will be critical. India's proposed bulk drug parks and Bangladesh's API industrial park are steps in the right direction.
• Manufacturing: The region is expected to increase its share of global generic drugs and biosimilars. Automation will be key to meeting high-quality standards at scale.
• Trade Integration: Deeper engagement with BIMSTEC and SAFTA could reduce barriers to intra-regional trade, creating a larger domestic market and reducing dependency on external partners.
• Energy Transition: Pharmaceutical manufacturing is energy-intensive. Transitioning to solar and other renewables can cut costs and improve sustainability credentials, aligning with global climate finance trends.
• Financial Markets: The growth of health care-focused venture capital and public listings will provide capital for innovators. India's recent biotech IPOs signal growing investor appetite.
• Innovation Ecosystems: Research universities and public research institutes in South Asia must strengthen ties with industry to commercialize discoveries. The establishment of biotech incubators in India and Sri Lanka is encouraging.
• Regional Cooperation: A collective approach to clinical trial harmonization, data sharing, and intellectual property enforcement would attract multinational R&D partnerships.
• Global Competitiveness: With a young workforce, escalating digital skills, and a proven manufacturing base, South Asia can become a top-tier player in the global life sciences arena, provided it navigates regulatory and geopolitical complexities wisely.

Conclusion

Deloitte's 2026 Life Sciences Outlook paints a picture of cautious global optimism, with individual companies feeling more secure than the overall economy. For South Asia, this distinction is a call to action. The region has the opportunity to build on its strengths—cost-competitive manufacturing, a skilled workforce, and growing digital maturity—while addressing its weaknesses in infrastructure, regulatory efficiency, and technology access. By aligning corporate strategies with long-term resilience and regional cooperation, South Asian life sciences can not only weather global uncertainties but also emerge as a defining force in the industry's next chapter.